Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509527 | 0.85 | HPGD (0.61) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL8144109 | 0.82 | PLA2G10 (0.59) | MEN1KMT2AKDM4ELMNAHPGD | |
| Hydrochloric Acid SCHEMBL8144384 | 0.81 | PLA2G10 (0.58) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL10055053 | 0.80 | ALDH1A1 (0.57) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL28496339 | 0.79 | MAPT (0.56) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL20545178 | 0.79 | HDAC1 (0.72) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL3916950 | 0.78 | RAB9A (0.61) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL3888099 | 0.78 | HPGD (0.61) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL4266853 | 0.78 | AKR1B1 (0.59) | MEN1KMT2AKDM4ELMNAHPGD | |
| SCHEMBL5315574 | 0.76 | HAO1 (0.59) | MEN1KMT2AKDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102448978-A | Novel Glucocorticoid Receptor Agonists | PFIZER LTD | 2012-05-09 | — | — | CN | disclosed |
| EP-2435462-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | Pfizer Limited (GB) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | NR3C1, NR3C2, MC2R | MEN1 3637/4885KMT2A 4072/4885KDM4E 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.